(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Veru's earnings in 2026 is -$22,726,279.On average, 6 Wall Street analysts forecast VERU's earnings for 2026 to be -$27,054,419, with the lowest VERU earnings forecast at -$37,750,353, and the highest VERU earnings forecast at -$21,908,687. On average, 4 Wall Street analysts forecast VERU's earnings for 2027 to be -$23,247,283, with the lowest VERU earnings forecast at -$23,908,557, and the highest VERU earnings forecast at -$22,245,744.
In 2028, VERU is forecast to generate -$15,634,617 in earnings, with the lowest earnings forecast at -$22,021,039 and the highest earnings forecast at -$8,594,946.